Search Results
Showing Results for Down syndrome
In this EAACI 2025 interview, Dr Remi Gagnon discusses his presentation on the TT-06 phase III trial. This was the first trial to investigate the SQ tree sublingual immunotherapy (SLIT) tablet in children aged 5–17 with tree pollen-induced allergic rhinitis and/or conjunctivitis. This interview explores the impact of seasonal allergies on quality of life and the background, design, and findings from the study.
On April 24, 2025, Brussels will host the 4th annual Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day, organized by EUFOREA. This year’s theme, "New Ambitions of Care," focuses on enhancing understanding of CRSwNP, improving early diagnosis, and promoting better treatment strategies for those affected by this debilitating condition.
GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
As 2024 comes to a close and as the new Patient Advisory Board & Advocacy Manager at EUFOREA, I have the privilege to reflect on the achievements and milestones of EUFOREA this year. With my background as a pharmacist and scientific ...
Paediatric sleep-disordered breathing Sleep-disordered breathing (SDB) is defined as the disruption of normal respiration and ventilation while asleep.1 SDB encompasses multiple sleep disturbances, ranging from mild snoring to obstructive sleep apnoea (OSA).1,2 OSA is characterized by episodic partial or complete ...
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and/or fibrosis.1Â Pulmonary fibrosis develops due to repeated cycles of injury and impaired repair with fibroblast activation and migration with the resultant deposition of extracellular matrix ...
Welcome to the latest issue of touchREVIEWS in Respiratory & Pulmonary Diseases, in which we bring you a range of topical and timely articles in the field of lung diseases. In this issue, we begin with an expert interview about ...
Obstructive sleep apnoea (OSA) is a widespread disorder that affects millions of individuals worldwide.1 It is characterized by repeated episodes of upper airway obstruction during sleep; these episodes can have several negative consequences, including daytime sleepiness, impaired quality of life ...
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary syndrome with a prevalence of approximately seven cases per 1 million individuals.1,2 PAP affects people of all age, sex, race and socioeconomic status. Based on the largest population studies conducted in the United ...
The definition of chronic obstructive pulmonary disease (COPD) has recently been reformulated better to encompass the heterogeneous nature of this lung condition.1Â The new definition is broader, includes risk factors other than smoking, and aims to improve the diagnosis, management ...
Burnout is the emotional and physical exhaustion that can be caused in a work environment, that results in depersonalization and reduced personal accomplishment. In health care professionals (HCP) burnout was exacerbated during the COVID-19 pandemic. In this touchRESPIRATORY interview, we ...
Night-time awakenings greatly affect the wellbeing of patients with severe asthma and challenges persist in its long-term treatment. touchRESPIRATORY were delighted to speak with Dr Warner Carr (Allergy & Asthma Associates of Southern California, A Medical Group; Southern California Research, ...
Interstitial lung disease (ILD) frequently complicates rheumatoid arthritis (RA).1 Moreover, it is more common among those who are male, smoke or are seropositive and with increasing age.1 Emergent risk factors include gain-of-function promoter variants in the MUC5B gene and ...
There is a wide range of eosinophil-associated disorders, from common conditions, such as eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), to rarer ones, such as eosinophilic gastrointestinal disorders and hypereosinophilic syndrome (HES). The advent of eosinophil-targeted therapies is ...
Dr Paula K Skarda is a hospitalist and primary internist and works for HealthPartners and Regions Hospital in Minnesota, USA. She has been in practice for 25 years after graduating from the University of Minnesota Medical School and completing the MedPeds ...
INVENT COVID was a phase II study, which investigated the efficacy and safety of intravenous imatinib in acute respiratory distress syndrome induced by COVID-19 (Clinical Trials Identifier: NCT04794088). touchRESPIRATORY were delighted to speak with Dr. Leila Atmowihardjo (Amsterdam Medical Centers: ...
Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
